NeuroOne Medical Technologies Corp 2025年季度报告

For theSix Months EndedMarch31, Debt termination costs reclassed to financing activities Prepaid expensesAccounts payable Accrued expenses, deferred revenue, operating leases and other liabilities(430,744)(420,194Net cash provided by (used in) operating activities151,905(5,984,554Investing activities Proceeds from issuance of common stock attributed to equity financings414,0373,350,467Issuance costs related equity financings(261,832)Financing costs in connection with debt facility(297,942)Share repurchases for the payment of employee taxes(118,372)Net cash (used in) provided by financing activities(264,109)3,165,207Net decrease in cash and cash equivalents(139,791)(2,887,838) Supplemental non-cash financing and investing transactions:Unpaid issuance costs in accounts payable and accrued expenses Modification of right-of-use asset and associated lease liability Purchased property and equipment in accounts payable$10,026$See accompanying notes to condensed financial statements NOTE 1 – Description of Business and Basis of PresentationNeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”), a Delaware corporation, is a medical technologycompany focused on the development and commercialization of thin film electrode for continuous electroencephalogram (“cEEG”)and stereoelectrocencephalography (“sEEG”) recording, monitoring, ablation, drug delivery and brain stimulation solutions todiagnose and treat patients with epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for therecording, monitoring, and stimulation of electrical signals at the subsurface level of the brain; and (iii) its OneRF ablation system forcreation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures. The Company has a distribution Generally, worldwide economic conditions remain uncertain, particularly due to the conflicts between Russia and Ukraine and in theMiddle East, disruptions in the banking system and financial markets, and increased inflation. The general economic and capitalmarket conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company’s activity on favorable terms or at all. If economic conditions continue to decline, the Company’s future cost of equity or debt capitaland access to the capital markets could be adversely affected. The Company does not currently anticipate any meaningful impact from current or proposed tariffs on imported goods.The Company’s operating results could be materially impacted by changes in the overall macroeconomic environment and othereconomic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflicts inUkraine and the Middle East, disruptions in the banking system and financial markets, and steps taken by governments and centralbanks, have led to higher inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy,including increased interest rates. condensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosuresrequired by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented notmisleading. These unaudited condensed financial statements should be read in conjunction with the audited financial statements andthe notes thereto for the year ended September 30, 2024 included in the Company’s Annual Report on Form 10-K. The condensed In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly thefinancial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. 5 NOTE 2 – LiquidityThe accompanying condensed financial statements have been prepared on the basis that the Company will continue as a goingconcern. The Company has incurred losses since inception, negative cash flows from operations since inception, and an accumulateddeficit of $75.5million as of March 31, 2025. To date, the Company’s revenues have not been sufficient to cover its full operating net proceeds of approximately $8.2million from the April 2025 Financing. The Company believes its current available cash and cashequivalents inclusive of the April 2025 Financing, coupled with the anticipated increase in product revenues from minimum purchases and improved gross margins under the Zimmer Amendment and forecasted operating expense reductions, will be sufficient to fund theCompany’s planned expenditures and meet its obligations for at least twelve months from the date of issuance